The final quarter often presents a challenge for pharmaceutical and medtech sales teams. As the year-end approaches, momentum can stall. In the NHS, this isn't about exhausted budgets but about navigating a system facing intense operational pressures. Access to key decision-makers tightens, and the detailed, value-based conversations required to progress product adoption are often deferred until the New Year. This dynamic can make achieving Q4 targets demanding.
This year, the usual Q4 slowdown is compounded by significant market friction. VPAG is, at the time of writing sky high at 23% of NHS sales, although the government may soon announce a new agreement under mounting industry pressure. Plus, the ABPI has noted the UK's decline in global rankings for pharmaceutical investment, a trend that can negatively influence the environment for innovation.
For field teams, the challenge is no longer about engaging a single clinician. It involves building a compelling case for bodies like Integrated Care Boards (ICBs). Gaining NICE approval is just the first step; the real work is demonstrating how a product improves patient pathways and delivers value across the health service. This requires Real-World Evidence (RWE) and a fundamental understanding of local priorities.
In the UK health system, the Q4 challenge is not one of exhausted annual budgets, but of navigating complex decision-making. Multi-year government plans set NHS spending priorities, and the organisation is under constant pressure to deliver value for money.
As decisions on adopting new medicines or technologies are frequently made at higher levels, the real work for field teams is demonstrating how a product integrates into and improves existing patient pathways. This requires presenting compelling RWE to clinicians and commissioners. The core challenge in Q4 is that the people needed for these detailed value conversations are the least available. The festive season is one of the most demanding periods for the health service. While many people enjoy a holiday, NHS staff are managing immense winter pressures, from seasonal flu and norovirus outbreaks to a rise in emergency admissions. This leaves little capacity for anything beyond immediate patient care.
How can organisations maintain momentum when the market slows, and internal resources are stretched? When waiting until January is not a viable strategy, several approaches can help maintain engagement and prepare for a strong start to the New Year.
When face-to-face access becomes difficult, a multi-channel strategy is essential. Supplement field team efforts with high-quality digital touchpoints. This could include targeted emails with valuable resources, invitations to on-demand educational webinars, or scheduling brief virtual meetings. It ensures your organisation remains visible and helpful, even without a physical visit.
An HCP's time is always limited, especially in Q4. Every interaction must provide high value. This means focusing on education that genuinely assists the professional and their patients, such as sharing new clinical data or RWE that supports pathway integration, rather than relying on old-fashioned sales tactics.
Use Q4 to nurture your strongest relationships. Re-engage with Key Opinion Leaders and existing advocates. While frontline HCPs are busy, these leaders may have time for more strategic, forward-planning conversations. Solidifying these partnerships in Q4 builds powerful advocacy and prepares momentum for your Q1 initiatives.
Q4 is an ideal time to review the year, make sure all conversations have been followed up and consolidate learnings. This allows teams to plan ahead for the new year, for example by organising peer-to-peer educational events for the January to March quarter. The team can feel confident, prepared and ready to start Q1 engaging HCPs with valuable and timely initiatives.
The Q4 period can be a great time for strategic reflection. Is your current team structure set up to enable a true account-based approach? While implementing this is a longer-term solution, asking the question now can shape future success. This model, where one contact holistically supports an HCP across a portfolio, builds deeper partnerships and avoids the volatility of single-product teams. CHASE can help your organisation understand how this works and learn best practice from across the industry.
Q4 is a good time to ask planning questions. Will your team require more flexibility in the next 12-18 months to manage fluctuating market demands or take advantage of opportunities? Now is a good time to look at options, while your field team may be quieter. An outsourced solution provides the agility to scale teams up or down as needed, ensuring you can act quickly and efficiently. Understanding these options now means you will be fully prepared for the year ahead.
The final quarter of 2025 demands more than just perseverance; it requires a strategic approach to resource. While the market context is challenging, Q4 sales targets remain. By anticipating the slowdown and implementing a flexible, multi-faceted strategy focused on demonstrating value, companies can bridge the gap. They can avoid the 'silent night' of a stalled pipeline and ensure they enter the New Year with active leads and established momentum.
Explore our latest thinking, event updates and industry insights to stay informed.
Discover 9 key trends shaping outsourced field teams in pharma and medtech for 2025, as they adapt to new NHS and healthcare sector challenges and demands.
.avif)
Learn how businesses impacted by the Employment Rights Bill can use outsourcing to reduce risk, save costs and enhance workforce management in healthcare.
Clinical pharmacists are key to primary care growth. Learn how pharma can engage this expanding workforce funded by government schemes for better patient care.
.svg)
